余莉芳
【摘要】 目的:了解Ⅲ度房室傳導(dǎo)阻滯行DDD起搏后的心功能變化,為臨床提供有效的心臟起搏方式。方法:136例Ⅲ度房室傳導(dǎo)阻滯患者被分為VVI組66例和DDD組70例,兩組置入的心臟起搏器分別為心室抑制型起搏(單腔起搏,VVI)和全自動(dòng)雙腔起搏(DDD)。兩組在術(shù)前和術(shù)后1年時(shí)觀察以下指標(biāo):左室收縮末徑(LVDs)、左室舒張末徑( LVDd)、左房?jī)?nèi)徑(LAD)、左心室后壁厚度(LVPWT)、室間隔厚度(IVS)、室壁增厚率(ΔT %)、左心室短軸縮短率(ΔD%),左室射血分?jǐn)?shù)(LVEF)、心臟指數(shù)(CI)、體循環(huán)血管阻力(SVR)、BNP水平。結(jié)果:術(shù)后1年,VVI組LVDd、LAD均明顯高于術(shù)前,差異均有統(tǒng)計(jì)學(xué)意義(t=5.199、4.748, P<0.05);術(shù)后1年,VVI組LAD顯著高于DDD組,差異有統(tǒng)計(jì)學(xué)意義(t=3.640,P<0.05)。術(shù)后1年,兩組BNP水平均比術(shù)前明顯升高,差異均有統(tǒng)計(jì)學(xué)意義(t=13.273、26.711,P<0.05);VVI組術(shù)后LVEF、CI均比術(shù)前明顯下降,差異均有統(tǒng)計(jì)學(xué)意義(t=7.881、6.218,P<0.05);術(shù)后1年,VVI組LVEF顯著低于DDD組, BNP顯著高于DDD組,差異均有統(tǒng)計(jì)學(xué)意義(t=5.905、11.853,P<0.05)。在隨訪期間,VVI組心房顫動(dòng)發(fā)生率為37.88 % (25/66),DDD組為8.57 % (6/70),差異有統(tǒng)計(jì)學(xué)意義(字2=16.580,P<0.05);VVI組缺血性腦卒中發(fā)生率為4.55%(3/66),DDD組為2.86%(2/70),差異無(wú)統(tǒng)計(jì)學(xué)意義(字2=0.273,P>0.05)。結(jié)論:對(duì)于Ⅲ度房室傳導(dǎo)阻滯患者,DDD起搏對(duì)心功能的影響更小,且術(shù)后心房顫動(dòng)發(fā)生率更低,具有良好的臨床應(yīng)用價(jià)值。
【關(guān)鍵詞】 Ⅲ度房室傳導(dǎo)阻滯; VVI起搏; DDD起搏; 左室射血分?jǐn)?shù); 血腦鈉素
doi:10.14033/j.cnki.cfmr.2017.31.071 文獻(xiàn)標(biāo)識(shí)碼 B 文章編號(hào) 1674-6805(2017)31-0142-04
【Abstract】 Objective:To learn the changes of cardiac function after DDD pacing on third degree atrioventricular block,and to provide an effective way of cardiac pacing.Method:136 cases with third degree atrioventricular block were divided into VVI group of 66 cases and DDD group of 70 cases,implanted cardiac pacemaker of the two groups were respectively ventricular inhibited pacing(single chamber pacing,VVI) and automatic dual chamber pacing(DDD).In preoperative and postoperative 1 year the following indicators of the two groups were observed:left ventricular end systolic diameter (LVDS),left ventricular end diastolic diameter (LVDD),left atrial diameter (LAD),left ventricular posterior wall thickness(LVPWT),interventricular septal thickness(IVS),ventricular wall thickening rate(ΔT%)and left ventricular short axis shortening(Δd%),left ventricular ejection fraction (LVEF),cardiac index (CI),systemic vascular resistance(SVR),brain natriuretic peptide (BNP) level.Result:1 year after surgery,LVDd and LAD of VVI group were significantly higher than preoperative,the differences were statistically significant(t=5.199,4.748,P<0.05).1 year after operation,LAD of VVI group was significantly higher than that of DDD group,the difference was statistically significant(t=3.640,P<0.05).1 year after operation,compared with preoperative,BNP level of two groups were increased significantly,the differences were statistically significant (t=13.273,26.711,P<0.05).Compared with preoperative,LVEF and CI of VVI group were decreased significantly,the differences were statistically significant(t=7.881,6.218,P<0.05).1 year after surgery,LVEF of VVI group was significantly lower than that of DDD group,BNP of VVI group was significantly higher than that of DDD group,the differences were statistically significant(t=5.905,11.853,P<0.05).During the follow-up period,atrial fibrillation incidence of VVI group was 37.88% (25/66),atrial fibrillation incidence of DDD group was 8.57% (6/70),the difference was statistically significant (字2=16.580,P<0.05).Ischemic stroke incidence of VVI group was 4.55%(3/66),ischemic stroke incidence of DDD group was 2.86% (2/70),the differences was not significant(字2=0.273,P>0.05).Conclusion:For patients with third degree atrioventricular block,the effect of DDD pacing on cardiac function is smaller,and the incidence of postoperative atrial fibrillation is lower,which has a good clinical value.endprint
【Key words】 Third degree atrioventricular block; VVI pacing; DDD pacing; Left ventricular ejection fraction; Brain natriuretic peptide
First-authors address:Shao yifu Hospital Affiliated to Zhejiang University Medical School,Hangzhou 310016,China
近年來(lái)研究表明,Ⅲ度房室傳導(dǎo)阻滯最有效的治療方法是置入埋藏式人工心臟起搏器,最常用的置入的心臟起搏器類型為心室抑制型起搏(單腔起搏,VVI)和全自動(dòng)雙腔起搏(DDD)[1-4]。置入人工心臟起搏器后對(duì)患者心功能及血流動(dòng)力學(xué)的影響是心臟起搏器的研究重點(diǎn)。正常的心房收縮所形成的輔助泵作用能有效提高患者心室舒張末期的左心室充盈量,采用超聲心動(dòng)圖等檢查顯示,與心室單腔起搏相比,心臟雙腔起搏能獲得更理想的血流動(dòng)力學(xué)狀況[5-6]。腦鈉素(brain natriuretic peptide,BNP)是人體心室肌細(xì)胞分泌的一種肽類活性因子,多項(xiàng)研究表明認(rèn)為BNP可較好地反映出血流動(dòng)力學(xué)狀況,可作為患者血流動(dòng)力學(xué)監(jiān)測(cè)的指標(biāo)[7]。為了了解Ⅲ度房室傳導(dǎo)阻滯行DDD起搏后的心功能變化,為臨床提供有效的心臟起搏方式,本文分析136例Ⅲ度房室傳導(dǎo)阻滯置入人工永久起搏器病例的臨床資料,現(xiàn)報(bào)告如下。
1 資料與方法
1.1 一般資料
選取2013年1月-2015年5月在筆者所在醫(yī)院心內(nèi)科就診的Ⅲ度房室傳導(dǎo)阻滯置入人工永久起搏器患者136例,所有病例均通過(guò)心電圖檢查確診為Ⅲ度房室傳導(dǎo)阻滯,竇房結(jié)功能均正常,均有置入人工永久起搏器適應(yīng)證。所有病例均排除嚴(yán)重瓣膜器質(zhì)性病變、急性心肌梗死、充血性心力衰竭、嚴(yán)重肝腎功能不全、嚴(yán)重慢性阻塞性肺疾病、惡性腫瘤等疾病。所選病例中男74例,女62例;年齡55~81歲,平均(67.4±6.2)歲;高血壓患者62例,冠心病患者35例。根據(jù)置入的人工永久起搏器種類分為VVI組66例和DDD組70例,患者均知情同意,本研究經(jīng)過(guò)醫(yī)院醫(yī)學(xué)倫理委員會(huì)通過(guò)。兩組患者性別、年齡等一般資料比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05),因而具有可比性。
1.2 手術(shù)方法
兩組置入的人工永久起搏器均為Medtronic公司產(chǎn)品,VVI組置入VVI起搏器,DDD組置入DDD起搏器,起搏器的電極導(dǎo)線種類均相同,心室采用CapSureFix Novus 5076型主動(dòng)電極導(dǎo)線,心房采用CapSureSense 4074 型被動(dòng)電極導(dǎo)線。所有病例均經(jīng)非優(yōu)勢(shì)手側(cè)鎖骨下靜脈置入電極導(dǎo)線,其中,將心室電極置于右心室的心尖部,將心房電極置于右心房耳部[8]。
1.3 觀察指標(biāo)
兩組置入起搏器后,均隨訪1年以上,在術(shù)前和術(shù)后1年時(shí)觀察以下各項(xiàng)指標(biāo)。采用 Philips Sonos 5500型彩色多普勒超聲診斷儀(荷蘭Philips公司),頻率2~4 MHz,測(cè)試3個(gè)心動(dòng)周期的左室收縮末徑(LVDs)、左室舒張末徑( LVDd)、左房?jī)?nèi)徑(LAD)、左心室后壁厚度(LVPWT)、室間隔厚度(IVS)、室壁增厚率(ΔT %)、左心室短軸縮短率(ΔD%),左室射血分?jǐn)?shù)(LVEF)、心臟指數(shù)(CI)、體循環(huán)血管阻力(SVR),數(shù)值取平均值。所有患者清晨空腹取靜脈血2 ml,4 ℃離心分離血漿,采用放射免疫分析法(IRA)檢測(cè)血漿中的BNP水平,檢測(cè)儀器試劑盒均購(gòu)自美國(guó)Biosite 公司,正常成人參考值為<250 pg/ml。以上操作嚴(yán)格按照儀器的說(shuō)明書執(zhí)行,試劑盒均在有效期內(nèi)使用。
1.4 統(tǒng)計(jì)學(xué)處理
應(yīng)用SPSS 22.0軟件對(duì)所得數(shù)據(jù)進(jìn)行統(tǒng)計(jì)分析,計(jì)量資料以(x±s)表示,采用t檢驗(yàn);計(jì)數(shù)資料以率(%)表示,采用字2檢驗(yàn),P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2 結(jié)果
2.1 兩組心臟形態(tài)結(jié)構(gòu)指標(biāo)比較
術(shù)前兩組LVDd、LVDs、LAD、LVPWT、IVS比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);術(shù)后1年,VVI組LVDd和LAD高于術(shù)前,差異均有統(tǒng)計(jì)學(xué)意義(t=5.199、4.748, P<0.05);術(shù)后1年,VVI組LAD高于DDD組,差異有統(tǒng)計(jì)學(xué)意義(t=3.640,P<0.05),見(jiàn)表1。
2.2 兩組血流動(dòng)力學(xué)指標(biāo)比較
術(shù)前兩組LVEF、ΔT %、ΔD%、CI、SVR、BNP比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);術(shù)后1年,兩組BNP水平均比術(shù)前明顯升高,差異均有統(tǒng)計(jì)學(xué)意義(t=13.273、26.711,P<0.05);VVI組術(shù)后LVEF、CI均比術(shù)前明顯下降,差異均有統(tǒng)計(jì)學(xué)意義(t=7.881、6.218,P<0.05);術(shù)后1年,VVI組LVEF低于DDD組, BNP高于DDD組,差異均有統(tǒng)計(jì)學(xué)意義(t=5.905、11.853,P<0.05),見(jiàn)表2。
2.3 兩組并發(fā)癥發(fā)生情況比較
在術(shù)后隨訪期間,VVI組中25例出現(xiàn)心房顫動(dòng),心房顫動(dòng)發(fā)生率37.88 % (25/66),DDD組中6例出現(xiàn)心房顫動(dòng),心房顫動(dòng)發(fā)生率8.57 % (6/70),差異有統(tǒng)計(jì)學(xué)意義(字2=16.580, P<0.05)。VVI組中3例出現(xiàn)缺血性腦卒中,缺血性腦卒中發(fā)生率為4.55 % (3/66),DDD組中2例出現(xiàn)缺血性腦卒中,缺血性腦卒中發(fā)生率為2.86 % (2/70),差異無(wú)統(tǒng)計(jì)學(xué)意義(字2=0.273,P>0.05)。
3 討論
大量臨床研究已證實(shí),置入人工心臟起搏器能有效降低Ⅲ度房室傳導(dǎo)阻滯的病死率,延長(zhǎng)患者的生存期,提高患者的生活質(zhì)量,然而長(zhǎng)期行人工心臟起搏可能會(huì)引起心律失常、心力衰竭,甚至腦卒中等嚴(yán)重并發(fā)癥[9-11]。endprint
在置入起搏器后的隨訪中發(fā)現(xiàn),與術(shù)前相比,VVI組和DDD組的LVEF值均有下降的趨勢(shì),而VVI組LVEF下降則有統(tǒng)計(jì)學(xué)意義,DDD組LVEF雖有所下降但并無(wú)統(tǒng)計(jì)學(xué)意義。文獻(xiàn)研究表明,右室心尖部起搏百分比是造成術(shù)后出現(xiàn)心力衰竭的危險(xiǎn)因素[12]。這是由于長(zhǎng)期行右室心尖部起搏會(huì)造成左心室傳導(dǎo)延遲,靜息心電圖顯示QRS時(shí)限增寬,此時(shí)雙心室收縮不同步會(huì)引起血流動(dòng)力學(xué)指標(biāo)改變。Ⅲ度房室傳導(dǎo)阻滯患者的右室起搏比例較高,因而術(shù)后的LVEF不同程度下降,這也支持了右室心尖部起搏是引起心功能異常的一種危險(xiǎn)因素。近年來(lái)的研究表明DDD起搏可防止左心室重構(gòu),可有效糾正左心室和右心室活動(dòng)的不同步,實(shí)現(xiàn)再同步,從而降低術(shù)后選擇性心力衰竭的發(fā)生率,降低患者的死亡率[13]。雙室起搏可糾正左右心室不同步,因而與右室起搏相比,給予慢性心房顫動(dòng)行房室結(jié)消融患者雙心室起搏更能有效保存左新室的功能[14]。另有研究表明,希氏束起搏和希氏束附近起搏十分接近于正常心室的激動(dòng)順序,術(shù)后可獲得較好的血流動(dòng)力學(xué)指標(biāo)檢測(cè)結(jié)果[15]。
BNP由心室肌細(xì)胞合成并分泌到血液中,當(dāng)機(jī)體的血管容量增加及血管壓力負(fù)荷升高時(shí),心室肌細(xì)胞會(huì)出現(xiàn)反應(yīng)性BNP分泌量升高,因而B(niǎo)NP水平可反映出左心室舒張末期壓力是否升高。文獻(xiàn)研究結(jié)果表明,外周血BNP水平可作為評(píng)價(jià)早期心功能損害的重要標(biāo)志物之一。在本文的研究張發(fā)現(xiàn),置入起搏器1年后,兩組的BNP水平均比術(shù)前明顯升高,VVI組BNP水平升高更顯著,這表明BNP水平可反映出置入人工心臟起搏器后的患者左心功能。
綜上所述,對(duì)于Ⅲ度房室傳導(dǎo)阻滯患者,DDD起搏對(duì)心功能的影響更小,且術(shù)后心房顫動(dòng)發(fā)生率更低,具有良好的臨床應(yīng)用價(jià)值。因而,對(duì)于無(wú)心房顫動(dòng)、房撲的Ⅲ度房室傳導(dǎo)阻滯患者,尤其是老年患者,推薦臨床治療中選擇置入DDD起搏器。
參考文獻(xiàn)
[1] Weder C,Monnet E,Ames M,et al.Permanent dual chamber epicardial pacemaker implantation in two dogs with complete atrioventricular block[J].J Vet Cardiol,2015,17(2):154-160.
[2]湯長(zhǎng)春,陳然,張翼,等.Ⅲ度房室傳導(dǎo)阻滯患者右心房起搏比例與心功能的關(guān)系[J].廣東醫(yī)學(xué),2012,33(7):935-937.
[3] Elles?e S G,Reimers J I,Andersen H ?.Normalisation of left ventricular systolic function after change from VVI pacing to biventricular pacing in a child with congenital complete atrioventricular block,long-QT syndrome,and congenital muscular dystrophy:a 10-year follow-up[J].Cardiol Young,2014,24(3):520-523.
[4]張曉宇,單其俊,宿燕崗,等.雙心室起搏預(yù)防高度房室傳導(dǎo)阻滯患者心功能不全的研究[J].中華心血管病雜志,2016,44(4):331-337.
[5]官文俊,謝進(jìn),許臣洪.雙腔起搏治療房室傳導(dǎo)阻滯對(duì)心臟收縮功能的影響[J].醫(yī)學(xué)研究雜志,2014,43(2):149-152.
[6] Lichtenberger J,Scollan K F,Bulmer B J,et al.Long-term outcome of physiologic VDD pacing versus non-physiologic VVI pacing in dogs with high-grade atrioventricular block[J].J Vet Cardiol,2015,17(1):42-53.
[7]楊玲,楊曉宇,柯海燕,等.Ⅲ度房室傳導(dǎo)阻滯患者雙腔起搏器植入術(shù)后血漿NT-proBNP水平的變化[J].江蘇醫(yī)藥,2014,40(21):2541-2544.
[8]湯長(zhǎng)春,向力群,胡美英,等.Ⅲ度房室傳導(dǎo)阻滯患者行不同房室間期起搏對(duì)血流動(dòng)力學(xué)及功能的影響[J].中國(guó)心臟起搏與心電生理雜志,2012, 26(1): 36-38.
[9]閆哲,豆穎,王明太,等.頻率適應(yīng)型雙腔起搏器對(duì)男性Ⅲ度房室傳導(dǎo)阻滯患者運(yùn)動(dòng)耐量和性生活質(zhì)量的影響[J].中國(guó)醫(yī)藥,2013, 8(11): 1544-1546.
[10]曹佳齊,崔克儉,丁躍有,等.右心室起搏與雙心腔起搏術(shù)對(duì)Ⅲ度房室傳導(dǎo)阻滯老年患者的臨床療效比較[J].國(guó)際心血管病雜志,2010,37(5):306-308.
[11]王婷婷,蔡尚郎,孫品,等.雙腔起搏器植入術(shù)后對(duì)三度房室傳導(dǎo)阻滯患者左心房功能的影響[J].心血管康復(fù)醫(yī)學(xué)雜志,2012, 21(3): 283-287.
[12] Bartczak K,Ammer A,Bartczak M,et al.Implantation of VVI epicardial pacemaker through mini-sternotomy in a patient with superior vena cava occlusion after radiotherapy[J].Kardiochir Torakochirurgia Pol,2014,11(1):69-70.
[13]徐鴻遠(yuǎn),李霖,黃創(chuàng),等.VVI型起搏器治療Ⅲ度房室傳導(dǎo)阻滯療效觀察[J].山東醫(yī)藥,2011, 51(5):59-61.
[14] Edwards S J,Karner C,Trevor N,et al.Dual-chamber pacemakers for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block:a systematic review and economic evaluation[J].Health Technol Assess,2015,19(65):1-210.
[15] Karjalainen P P,Nammas W,Paana T.Transcatheter leadless pacemaker implantation in a patient with a transvenous dual-chamber pacemaker already in place[J].J Electrocardiol,2016,49(4):554-556.
(收稿日期:2017-07-17)endprint